If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today

Back then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days.It's a good bet that, five years ago, the average American investor would not have been familiar with Novo Nordisk (NVO 0.29%). That's because the Denmark-based company had not yet won U.S. Food and Drug Administration (FDA) approval for its star drug, weight loss treatment Wegovy.What a difference five years and several regulatory nods can make. Novo Nordisk has rocketed to prominence on the back of W ...